Eli Lilly and
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $24,397,000 | $22,974,000 | $19,799,000 | $19,292,000 |
Gross Profit | 20,464,000 | 19,706,000 | 16,222,000 | 15,920,300 |
EBITDA | 9,329,000 | 12,991,000 | 10,287,000 | 12,144,500 |
EBIT | 8,784,000 | 12,457,000 | 9,778,000 | 11,558,800 |
Net Income | 6,451,000 | 7,095,000 | 7,396,000 | 6,637,700 |
Net Change In Cash | 24,397,000 | 22,974,000 | 19,799,000 | 19,292,000 |
Free Cash Flow | 8,219,000 | 7,757,000 | 3,007,000 | 677,900 |
Cash | 4,885,000 | 8,890,000 | 5,136,000 | 7,163,000 |
Basic Shares | 893,400 | 893,700 | 895,900 | 898,002 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $65,179,000 | $45,043,000 | $34,124,100 | $28,541,400 |
Gross Profit | 54,127,000 | 36,625,000 | 27,041,900 | 21,911,600 |
EBITDA | 31,693,000 | 18,807,000 | 8,567,800 | 8,660,500 |
EBIT | 29,696,000 | 17,040,000 | 7,040,500 | 7,138,000 |
Net Income | 20,640,000 | 10,590,000 | 5,240,400 | 6,244,800 |
Net Change In Cash | 65,179,000 | 45,043,000 | 34,124,100 | 28,541,400 |
Cost of Revenue | -1,583,900 | |||
Free Cash Flow | 8,972,000 | 3,760,100 | -3,152,000 | 4,600,400 |
Cash | 7,163,000 | 3,268,400 | 2,818,600 | 2,067,000 |
Basic Shares | 898,002 | 904,059 | 903,284 | 950,182 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | $7.48 |
2026-06-30 | $8.38 |
2026-03-31 | $8.55 |
2025-12-31 | $7.54 |